Medigen Biotechnology Corp. (TPEX:3176)

Revenue by Segment

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
New Drugs and Vaccine Development			389.62M	365.04M	3.28B	-	96.32M
New Drugs and Vaccine Development Growth			6.73%	-88.85%	-	-	-
Adjustments and Eliminations			-2.70M	-	-	-	-1.34M
Nucleic Acid Test			61.73M	83.79M	98.34M	98.69M	75.82M
Nucleic Acid Test Growth			-26.33%	-14.80%	-0.36%	30.17%	-29.61%
Generic Drugs and Medical Aesthetic Products Department and Health Food Department			709.07M	606.52M	536.53M	505.12M	364.88M
Generic Drugs and Medical Aesthetic Products Department and Health Food Department Growth			16.91%	13.05%	6.22%	38.43%	8.12%
Cell Therapy Department			-	600.00K	11.98M	11.73M	16.66M
Cell Therapy Department Growth			-	-94.99%	2.14%	-29.58%	-
Total			1.16B	1.06B	3.92B	615.54M	552.35M
Total Growth			9.64%	-73.08%	537.17%	11.44%	35.61%

Revenue by Geography

Financials in millions TWD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Taiwan			1.15B	1.01B	3.85B	543.23M	402.67M
Taiwan Growth			14.03%	-73.87%	608.39%	34.91%	1.27%
China			6.30M	39.59M	53.04M	40.86M	36.64M
China Growth			-84.10%	-25.36%	29.81%	11.53%	449.84%
Other			4.96M	10.97M	20.79M	31.45M	114.38M
Other Growth			-54.82%	-47.22%	-33.90%	-72.50%	179.46%
Discontinued Operations			-	-	-	-	-1.34M
Total			1.16B	1.06B	3.92B	615.54M	552.35M
Total Growth			9.64%	-73.08%	537.17%	11.44%	35.61%

Source: S&P Global Market Intelligence.